Corning Jireh Pharmaceutical-B (09966): JSKN033 has received approval from the CDE to conduct a Phase III clinical study for the treatment of cervical cancer.

According to the Zhiyin Financial APP, Corning Jereh Pharmaceutical-B (09966) announced that JSKN033 (a high-concentration subcutaneous injection compound formulation composed of a human epidermal growth factor receptor 2 (HER2) bispecific antibody-drug conjugate (ADC(s)) and a programmed death ligand 1 (PD-L1) immune checkpoint inhibitor) has obtained approval from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to conduct a Phase III clinical study (Study No.: JSKN033-301) for monotherapy in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and PD-1/PD-L1 inhibitor treatment.